Acupuncture with a jolt: new hope for shingles nerve pain?
NCT ID NCT04560361
First seen Jun 25, 2026 · Last updated Sep 11, 2026 · Updated 3 times
Summary
This completed trial tested whether electroacupuncture (acupuncture with a mild electric current) can reduce pain in people with postherpetic neuralgia, a lingering nerve pain after shingles. 448 adults aged 45-75 with moderate-to-severe pain were randomly assigned to real or sham electroacupuncture. The main goal was to see if pain scores dropped by at least 30%.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- electroacupuncture
- What this could lead to
- If it works, this could offer a non-drug option for managing nerve pain after shingles.
- What could go wrong
- The trial is completed but results are not yet widely confirmed. Sham acupuncture may also provide some relief, making it hard to know the true effect.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
448 people
The number who actually took part.
- Started
-
Oct 2020
- Finished
-
Sep 2022
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
45 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients who meet the diagnostic criteria for postherpetic neuralgia (with a clear history of acute herpes zoster, and the duration of postherpetic pain exceeds 90 days) * Aged 45 to 75 years old * Patients who were diagnosed with moderate or above pain during the observation period (the daily pain score was continuously collected within 7 days during the observation period, and the average NRS-11 pain score was \>=4) * Subjects who did not participate in other ongoing clinical studies * Sign informed consent and volunteer to participate in the study Exclusion Criteria: * Patients who are currently receiving or receiving more than one of the "permitted combinations" or any "prohibited combination and treatment" for PHN listed in the following part at least 14 days before screening, and are unwilling to undergo washout period, or patients with serious safety problems during washout period or observation period * Patients who are expected to receive any new prescription drug or other treatment for PHN after the start of the trial * Patients with serious uncontrolled medical conditions, such as cardiovascular, lung, liver, kidney, gastrointestinal tract, metabolism, endocrine, nervous system, respiratory system, urogenital system and other serious diseases, or systemic organ dysfunction, malignant tumor, hematologic disease such as bleeding tendency or coagulation dysfunction, serious mental illness such as depression or schizophrenia Symptoms, hepatitis B antigen or hepatitis C antibody positive known state or history of immune dysfunction, history of HIV infection, etc. * Patients with severe pain unrelated to PHN, such as after surgery for clinical major diseases * Patients with PHN who have received nerve intervention or other neurosurgical treatment, such as selective nerve damage, percutaneous radiofrequency thermocoagulation or pulsed nerve modulation technology, etc. * Patients with some special types of herpes zoster, such as those with meninges, cornea, conjunctiva, ear involvement, visceral herpes zoster, generalized herpes zoster * Patients with skin ulceration, new herpes, or skin infection * Patients with cardiac pacemaker, metal allergy or severe fear of needle * Patients who are unable to give full informed consent or cannot cooperate with pain scale assessment due to mental, mental, linguistic or behavioral disorders * Patients who have poor compliance or are prone to fall off due to other reasons, such as the current residence is not in the city where the recruitment hospital is located, or the working environment changes frequently * Pregnant and lactating women
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Postherpetic neuralgia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huai'an Hospital of Traditional Chinese Medicine
Huai'an, Jiangsu, 223001, China
-
Jiangsu Province Hospital of Chinese Medicine
Nanjing, Jiangsu, 210029, China
-
Lianyungang Hospital of Traditional Chinese Medicine
Lianyungang, Jiangsu, 222004, China
-
Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine
Nanjing, Jiangsu, 210001, China
-
Nantong Hospital of Traditional Chinese Medicine
Nantong, Jiangsu, 226001, China
-
Shuyang Hospital of Traditional Chinese Medicine
Suqian, Jiangsu, 223600, China
-
Wuxi Hospital of Traditional Chinese Medicine
Wuxi, Jiangsu, 214071, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New gel promises shingles pain relief in minutes
- Can nerve zapping predict who gets pain relief from shingles?
- New hope for shingles pain sufferers: drug trial underway
- New drug shows promise for shingles nerve pain
- Shingles pain relief showdown: nerve block vs radiofrequency
- Zapping away shingles pain: new trial tests pulsed radiofrequency